arrow
V

Vı́ctor Vargas

universidad autónoma de barcelona
H-index:61
Citation Count:1.8万
Views:0

Biography

No content for now.

Education

No content for now.

Work Experience

No content for now.

Honors & Awards

No content for now.

Factors associated with progression, resolution and mortality of patients with overt hepatic encephalopathy

与显性肝性脑病患者进展、缓解和死亡率相关的因素

2025-11-070
PRE
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome

特利加压素在肝硬化及急性肾损伤中的实际应用:超越肝肾综合征的频繁使用

2025-09-080
OAAI
Targeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease

靶向抑制致病共生菌毒力因子可缓解酒精性肝病

2025-05-280
PRE
Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.

频繁的ATP7B突变的低外显率解释了威尔逊病的低患病率。现实生活中的注册经验教训。

2025-02-010
PRE
Application of a novel higher-order stretchable kinematic model for electro-elastic response analysis of constrained cylindrical shell
2024-11-071
PRE
Bacterial Infection Features in Alcohol-Associated Hepatitis: Review of a 2016-2021 Cohort

酒精相关性肝炎的细菌感染特征: 2016 2021队列的回顾

2024-09-250
OAAI
Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis
2024-09-250
PRE
Frailty and sarcopenia in patients with acute-on-chronic liver failure: Assessment and risk in the liver transplant setting
2024-09-011
OAAI
Development and external validation of a model to predict multidrug-resistant bacterial infections in patients with cirrhosis
2024-08-152
PRE
Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design
2024-08-010
OAAI
Prophylactic antibiotics in patients with alcohol-associated hepatitis receiving steroids: A systematic review and meta-analysis
2024-06-222
OAAI
An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study

人工智能生成的模型预测酒精相关性肝炎的90天生存率: 一项全球队列研究

2024-04-123
PRE
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

Elafibranor在原发性胆汁性胆管炎中的疗效和安全性

2024-02-2945
PRE
Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis
2024-02-201
PRE
Photoluminescence modification of europium(iii)-doped MAl2O4 (M = Zn, Mg) spinels induced by Ag@SiO2 core-shell nanoparticles (Jun, 10.1039/D4NR01526F, 2024)
2024-01-010
OA
Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections-Results from the ICA Global Study (EABCIR-Global Study)
2023-12-014
PRE
MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis
2023-08-0112
OAAI
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
2023-04-0645
OAAI
Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study
2022-08-242
OAAI
Final safety and efficacy results from a 106 real-world patients registry with an ascites-mobilizing pump
2022-07-257
OAAI